Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1=Etanercept · 1 trial · 1 indication
The percentage of participants with the Psoriasis Area and Severity Indexs (PASI) 75 responses at week 12. PASI is an assessment of psoriasis based on severity of erythema, infiltration, and desquamation as well as area of involvement. The PASI score ranges from 0 to 72. The higher score represents the worse symptom severity. A response was considered a 75% reduction in the PASI score from Baseline.
| Arm | Type | Description |
|---|---|---|
| etanercept and clobetasol | EXPERIMENTAL | Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24) |
| etanercept | EXPERIMENTAL | Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks |
| Name | Type | Description |
|---|---|---|
| 1=Etanercept | DRUG | 50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks. |
| 2=Clobetasol propionate foam | DRUG | 0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses |
Inclusion Criteria: * Subject has had stable moderate to severe plaque psoriasis for at least 6 months * Subject has involved BSA ≥ 10% and PASI ≥ 10 at screening and at baseline. * Subject is a candidate for systemic therapy or phototherapy in the opinion of the investigator Exclusion Criteria: ...
Etanercept is used for the treatment of moderate to severe plaque psoriasis. It is being investigated as a topical therapy combined with etanercept in a Phase 3 clinical trial. The study enrolled 592 participants aged 18 years and older with psoriasis.
Etanercept is developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The company is conducting clinical research to evaluate the efficacy and safety of etanercept for the treatment of moderate to severe plaque psoriasis.
Etanercept is in Phase 3 clinical development for the treatment of moderate to severe plaque psoriasis. The Phase 3 trial has been completed, with a total enrollment of 592 participants. Etanercept remains an investigational drug for this indication and is not yet approved.
Etanercept is associated with one completed Phase 3 clinical trial registered as NCT01235442. The trial, titled 'Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis,' enrolled 592 participants and was a controlled, randomized study.
Yes, Etanercept is classified as a small molecule therapeutic. It is being studied in the dermatology therapeutic area for the treatment of psoriasis. The Phase 3 clinical trial evaluating etanercept was a controlled study with 592 enrolled participants.